stenosis (AS). [1] [2] [3] [4] [5] [6] [7] Although technical development led to a reduced complication rate, 8 it is also recognized that some patients do not derive a benefit in function, morbidity, or mortality after TAVR. Those patients are often characterized by risk factors and a variety of comorbidities not represented in currently applied surgical risk scores. 9 Futility is a generic term describing a lack of medical efficacy and although there is no uniform definition, 10 from a TAVR perspective futility is usually defined by the combination of death and/or absence of functional improvement during short-term follow up at 6-12 months.
11
Although there are no reliable data, the coincidence of severe aortic stenosis and cancer disease seems to be clinically relevant. 12 In addition, cancer is also a common reason to decline surgical aortic valve replacement (SAVR). 13 Decision making is particularly complex in patients with cancer disease since prognosis is often uncertain.
However, in a retrospective analysis, Yusuf et al showed that cancer patients undergoing SAVR had a better survival compared to medically treated patients. 12 Contradictory, patients with a hematological cancer disease had an increased rate of perioperative mortality and morbidity after open heart surgery, predominantly due to infectious complications. 14 In this context, little is known about patients undergoing TAVR that are either currently suffering from an active cancer disease (ACD) or that previously had a tumor disease (HCD). One study including 47 cancer patients undergoing TAVR found similar acute outcomes and midterm survival rates compared to non-cancer patients in Japan. 15 But data are still limited and, therefore, we aimed to determine the prevalence, clinical characteristics, perioperative outcomes, and 1-year mortality of patients with severe aortic stenosis and ACD undergoing TAVR in a real-world cohort of patients treated in a single center.
| METHODS

| Patient cohort
From 02/2006 to 09/2014, a total of 1821 consecutive patients were treated with a transfemoral transcatheter aortic valve replacement (TF-AVR) in our tertiary center after discussion of the best treatment option in a multidisciplinary heart team. 16 Data about the prevalence of an ACD or HCD at the time point of implantation were available in all patients and were prospectively collected. Baseline characteristics, procedural data and outcome data were also prospectively collected.
Follow-up was performed after 30 days and 12 months. All end point definitions were subject to the Valve Academic Research Consortium II definitions. 17 The study was approved by the Ethics Committee of the University of Leipzig (registration number: 167-10-12072010) and all patients gave written informed consent.
| Diagnosis of cancer disease
Diagnosis of ACD was taken from the medical history of the patient and included those patients having a non-cured cancer disease. Only patients with confirmed diagnosis of an ACD by a specialist (eg, 
| Endpoints
All-cause mortality at 1 year was the primary end point of the analysis. To evaluate the further development of survival, 3-year mortality was also analyzed. Furthermore, 1-year and 3-year mortality was subdivided into cardiovascular and non-cardiovascular mortality according to the definition of Valve Academic Research Consortium 2 (VARC-2). 17 Cause of death was verified by two authors (NM, FJW) reviewing medical records and death certificates to receive consensus. According to VARC-2, patients with unknown cause of death were categorized as cardiovascular mortality.
Improvement of the functional status was assessed by the New 3 | RESULTS
| Prevalence of ACD and baseline characteristics
Ninety nine patients (5.4%) suffered from ACD compared to 251 patients (13.8%) with HCD and 1471 patients (80.8%) without ACD/ HCD (control). ACD was attributable to a solid organ or to hematological origin in 72.2% and 27.3% of the patients, respectively.
In male patients, prostate cancer (42.4%) followed by hematological cancer (23.7%) and colon cancer (6.8%) were the most common forms.
In female patients, breast cancer (35.0%) followed by hematological cancer (30.0%) and colon cancer (17.5%) were the most common forms (Table 1) .
Thirty seven patients (37.4%) suffered from an advanced cancer disease state with 29 patients (29.3%) having evidence of metastasis.
Fifty patients (50.5%) were under current cancer therapy, whereas 23 patients (23.2%) were in a "watch-and-wait" strategy. Seventeen patients (17.2%) were sent for treatment of severe AS first to be followed by specific cancer therapy. The remaining nine patients were managed with a palliative strategy. Patients with ACD were more often male (P = 0.002) and had a lower logisticEuroScore I (P = 0.027) whereas STS score was comparable between groups. All other baseline characteristics including age, arterial hypertension, coronary artery disease, peripheral artery disease, chronic lung disease, and chronic kidney disease were comparable between groups (Table 2) .
| Procedural data and complications
Indication, type of valve and procedural success rate did not differ between the groups (Table 3) . Complication rate at 30 days including myocardial infarction, stroke, kidney injury, bleeding, and vascular access site complication did also not vary between groups (Table 3 ).
The combined endpoint of VARC defined device success did not differ between groups.
| Mortality and functional outcome
Thirty-day mortality did not differ between ACD, HCD, and controls (6.1% vs 4.4% vs 7.6%, P = 0.176). In contrast, all-cause 1-year mortality was significantly higher in patients with ACD compared to those with HCD and controls (37.4% vs 16.4% vs 20.8%, P < 0.001). A landmark analysis starting beyond day 30 revealed an even higher mortality difference between patients with ACD compared to those with HCD and controls (33.3% vs 12.6% vs 14.3%, P < 0.001) ( Figure 1A ). Noncardiovascular mortality was the main contributor for the increased 1-year mortality and was higher in patients with ACD compared to HCD and controls (17.2% vs 4.0% vs 3.6%, P < 0.001) ( Figure 1B ). The increased non-cardiovascular mortality at 1 year was attributable to the cancer disease itself in 66.7% followed by infectious causes (16.7%). In the remaining three cases, death was caused by renal failure, liver failure and acute abdomen, presumably bowl ischemia. In contrast, cardiovascular mortality at 1 year was only numerically higher in patients with ACD compared to HCD and controls but did not reach statistical significance (20.2% vs 12.4% vs 17.2%, P = 0.069) ( Figure 1B ). These findings persisted up to 3 years after intervention with a higher all-cause (47.5% vs 27.6% vs 30%, P < 0.001) and non-cardiovascular mortality (25.3% vs 7.6% vs 5.9%, P < 0.001) but not cardiovascular mortality with a watch-and-wait strategy had the best survival whereas TAVR prior to planned specific cancer treatment or palliative situation were associated with worse outcome at 1 year according to a landmark analysis (17.4% vs 29.5% vs 52.9% vs 55.6%, P = 0.02, Figure 2C ).
Comparing patients with active hematological and solid organ related cancer, no difference was detected regarding all-cause 1-year mortality Figure 2A ), whereas in female patients those with active breast cancer had a comparable mortality compared to all other cancer forms (25.0% vs 32.0%, P = 0.716, Figure 2B ). A multivariate Cox regression analysis revealed, besides others, ACD as an independent predictor of all-cause 1-year mortality (HR 2.10, 95%CI 1.41-3.13, P < 0.001) ( Table 4) .
Despite similar valve and cardiac function (Table 3) , patients with ACD and HCD remained more symptomatic at 1 year indicated by a higher proportion of patients still in NYHA III/IV (9.2% vs 16.7% vs 17.0%, P = 0.006) (Figure 3 ).
| DISCUSSION
The purpose of this investigation was to determine the prevalence, . 18 TAVR, in particular using a transfemoral access, is less invasive and might be theoretically a better option for those cancer patients exhibiting a high bleeding risk. Indeed, in our study, the TAVR procedure itself led to the same device success without an increase of any VARC-II defined complication or 30-day mortality in ACD compared to controls. Therefore, one may consider TAVR as a safe and effective therapeutic option for those patients and current expert opinions judge TAVR as a suitable option in this situation. 19 After day thirty, however, there is a 2.3-fold increase in mortality in ACD compared to controls which is mainly driven by a higher noncardiovascular mortality attributable to the cancer disease itself and infectious causes of death. These findings persist up to 3 years after intervention; however, mortality is highest within the first year after intervention in ACD. Causes of long-term death in other TAVR cohorts are also mainly non-cardiovascular including sepsis/infection and cancer, 20, 21 which indicates that identifying futile patients may improve outcome of TAVR. This is also related to current guidelines suggesting intervention only in patients with a life expectancy of at least 1 year. 22, 23 Generally, in our investigation patients only received TAVR if life expectancy was judged to be more than 1 year by the treating oncology specialist. But decision making about life expectancy in cancer patients is challenging, particularly in those that lay on the exterior of the Gaussian distribution curve, which may therefore lead on the one hand to a refusal of patients who might benefit and on the other hand to treatment of potentially futile patients. In our cohort, patients having a limited cancer disease state, those managed with a "watch-and-wait" strategy (eg, chronic lymphatic leukemia) and males with prostate cancer had a better survival suggesting that those patients might be considered as patients who benefit from TAVR. In contrast, patients with advanced cancer disease, treated with a palliative management or received TAVR prior to a specific cancer therapy were at the highest risk for mortality considering them as potentially futile patients. Other treatment options (eg, balloon aortic valvuloplasty) should be considered in patients with advanced cancer disease state or palliative treatment strategy for symptom relief.
Furthermore patients with an uncertain prognosis who need to be conditioned prior to a specific cancer therapy should also be treated with balloon aortic valvuloplasty to avoid heart failure. 24, 25 After 1 year, a trend to a higher cardiovascular mortality was observed. There are at least two possible explanations for this finding.
First, a methodological one due to the fact that death from unknown cause is classified as cardiovascular death according to VARC-2, and second, certain cancer treatment is known to exhibit cardiovascular toxicity and, therefore, patients under current treatment may have an Abbreviations as in Table 1 and 2. increased risk for heart failure, myocardial ischemia, or thromboembolism. 19 However, the trend toward a higher cardiovascular mortality disappeared after 1 year; supporting the first explanation and suggesting that this finding is by chance. Our results are in contrast to the study by Watanabe et al 15 reporting unaffected 1-year mortality in Japanese cancer patients compared to controls. Variances in tumor type distribution and racial disparities might have contributed to this difference. Furthermore, our study included 99 cancer patients compared to 47 by the Japanese study resulting in a higher event rate and power. 15 However, at least patients with metastasis had a higher mortality in the study from Japan reflecting our cohort of patients with advanced cancer disease state. Furthermore, the prevalence of ACD was comparable between both TAVR cohorts (5.4% vs 6.3%). 15 Our mortality rate is also higher than those reported in cancer patients treated by SAVR 12 which is mainly attributable to a large age-related difference between the two study samples (80 vs 69 years of age).
Beyond survival, the question remains if patients undergoing TAVR have a symptomatic and quality-of-life benefit or if other conditions determine their state of health. 11 We were only able to assess NYHA class at 12 months as a surrogate of symptom improvement and found that both ACD and HCD remained more symptomatic with a higher proportion of patients in NYHA III/IV despite similar valve and cardiac function. This suggests that not only AS contributes to the limitations in those patients but genesis of symptoms is multifactorial.
Our study has several limitations that should be noted. The number of cancer patients is still low despite being, to the best of our knowledge, the biggest study investigating cancer patients undergoing TAVR. Therefore, the complex evaluation of prognosis for specific cancer types and their different tumor stages could not be performed but should be investigated in future multicenter registries. To have some understanding on prognosis, we have chosen the classifications according to advanced versus limited cancer disease and the overall treatment plan, which is practical and can be easily obtained from medical history.
However, the findings should be interpreted cautiously and hypothesis generating since they do not do justice to the complex biology and prognosis of different cancer types at different disease stages.
Last but not least, data collected were derived from a single center registry and are, therefore, prone to bias inherent to registries and not necessarily conferrable to other cohorts.
In conclusion, patients with severe aortic stenosis and concomitant active cancer disease undergoing TAVR have a higher 1-year mortality compared to patients with a history of cancer disease or controls. This should be taken into account since active cancer disease is not reflected in conventional risk scores and the need for identifying the subgroup of patients in whom TAVR is likely to be futile remains a priority. Individual decision making is necessary due to the fact that certain tumor entities and disease stages seem not to be associated with an excessive mortality compared to others.
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FIGURE 3
Symptom status over time. Symptom status according to New York Heart Association (NYHA) class is shown at baseline and 1 year among controls, patients with a history of cancer disease (HCD) and with active cancer disease (ACD). At baseline, no difference was detectable between groups for NYHA I/II versus III/IV (P = 0.700) whereas more patients with ACD and HCD remained in NYHA III/IV after 1 year (P = 0.006)
